Abstract
Hypoxia is a common characteristic of solid tumors. It is mainly determined by low levels of oxygen resulting from imperfect vascular networks supplying most tumors. In an attempt to improve the present chemotherapeutic treatment and reduce associated side effects, several prodrug strategies have been introduced to achieve hypoxia-specific delivery of cytotoxic anticancer agents. With the advances in nanotechnology, novel delivery systems activated by the consequent outcomes of hypoxia have been developed. However, developing hypoxia responsive drug delivery systems (which only depend on low oxygen levels) is currently naïve.
This review discusses four main hypoxia responsive delivery systems: polymeric based drug delivery systems, oxygen delivery systems combined with radiotherapy and chemotherapy, anaerobic bacteria which are used for delivery of genes to express anticancer proteins such as tumor necrosis alpha (TNF-α) and hypoxia-inducible transcription factors 1 alpha (HIF1α) responsive gene delivery systems.
Keywords: Tumor hypoxia, delivery systems, nitroimidazole, azobenzene, metal complexes, oxygen carriers.
Current Pharmaceutical Design
Title:Hypoxia Responsive Drug Delivery Systems in Tumor Therapy
Volume: 22 Issue: 19
Author(s): Houman Alimoradi, Siddharth S. Matikonda, Allan B. Gamble, Gregory I. Giles and Khaled Greish
Affiliation:
Keywords: Tumor hypoxia, delivery systems, nitroimidazole, azobenzene, metal complexes, oxygen carriers.
Abstract: Hypoxia is a common characteristic of solid tumors. It is mainly determined by low levels of oxygen resulting from imperfect vascular networks supplying most tumors. In an attempt to improve the present chemotherapeutic treatment and reduce associated side effects, several prodrug strategies have been introduced to achieve hypoxia-specific delivery of cytotoxic anticancer agents. With the advances in nanotechnology, novel delivery systems activated by the consequent outcomes of hypoxia have been developed. However, developing hypoxia responsive drug delivery systems (which only depend on low oxygen levels) is currently naïve.
This review discusses four main hypoxia responsive delivery systems: polymeric based drug delivery systems, oxygen delivery systems combined with radiotherapy and chemotherapy, anaerobic bacteria which are used for delivery of genes to express anticancer proteins such as tumor necrosis alpha (TNF-α) and hypoxia-inducible transcription factors 1 alpha (HIF1α) responsive gene delivery systems.
Export Options
About this article
Cite this article as:
Alimoradi Houman, Matikonda S. Siddharth, Gamble B. Allan, Giles I. Gregory and Greish Khaled, Hypoxia Responsive Drug Delivery Systems in Tumor Therapy, Current Pharmaceutical Design 2016; 22 (19) . https://dx.doi.org/10.2174/1381612822666160217130049
DOI https://dx.doi.org/10.2174/1381612822666160217130049 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Epigenetic Remodeling of Chromatin Architecture: Exploring Tumor Differentiation Therapies in Mesenchymal Stem Cells and Sarcomas
Current Stem Cell Research & Therapy Oral Precancerous Lesions Show Increased Levels of Glutathione Compared to Cancerous Tissue
Current Nutrition & Food Science Progress in Nutritional and Health Profile of Milk and Dairy Products: A Novel Drug Target
Endocrine, Metabolic & Immune Disorders - Drug Targets The Universal Nature, Unequal Distribution and Antioxidant Functions of Melatonin and Its Derivatives
Mini-Reviews in Medicinal Chemistry New Analytical Tools for Studying Autoimmune Diseases
Current Pharmaceutical Design Assessment of a Synthetic Steroid and Flutamide on Dopamine, GSH and H<sub>2</sub>O<sub>2</sub> Levels in Rat Brain in Presence of Fructose
Endocrine, Metabolic & Immune Disorders - Drug Targets Notch Signaling: A Potential Therapeutic Target in Prostate Cancer
Current Cancer Drug Targets Peptides Targeting Gap Junctional Structures
Current Pharmaceutical Design Pharmacological Management of Type 2 Diabetes Mellitus: An Update
Current Diabetes Reviews Combined Effect of Parthenolide and Various Anti-cancer Drugs or Anticancer Candidate Substances on Malignant Cells in vitro and in vivo
Mini-Reviews in Medicinal Chemistry 2D QSAR Studies on a Series of Quinazoline Derivatives as Tyrosine Kinase (EGFR) Inhibitor: An Approach to Design Anticancer Agents
Letters in Drug Design & Discovery Stem Cell and Gene Therapeutic Strategies for the Treatment of Multiple Sclerosis
Current Molecular Medicine Glycolipid Antigen – Mediated Invariant NKT Cell Activation in Microbial Immunity
Current Immunology Reviews (Discontinued) 2-Mercaptobenzothiazole and its Derivatives: Syntheses, Reactions and Applications
Current Organic Chemistry A hypothesis for the role of RECK in angiogenesis
Current Vascular Pharmacology Tannic Acid Inhibits Proliferation, Migration, Invasion of Prostate Cancer and Modulates Drug Metabolizing and Antioxidant Enzymes
Anti-Cancer Agents in Medicinal Chemistry Regulation of Multidrug Resistance by Pro-Inflammatory Cytokines
Current Cancer Drug Targets Pro-apoptotic Activity of BH3-only Proteins and BH3 Mimetics: from Theory to Potential Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Inhibition of Bacterial Carbonic Anhydrases and Zinc Proteases: From Orphan Targets to Innovative New Antibiotic Drugs
Current Medicinal Chemistry Green Tea Catechins as Novel Antitumor and Antiangiogenic Compounds
Current Medicinal Chemistry - Anti-Cancer Agents